Secondary Logo

Journal Logo

September/October 2022 - Volume 42 - Issue 5

  • Anthony J. Rothschild, MD
  • 0271-0749
  • 1533-712X
  • 6 issues / year
  • Psychiatry 101/155; Pharmacy and Pharmacology 170/279
  • 3.118
A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia

This continuing education supplement is jointly provided by Medical Education Resources and CMEology. The supplement is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. It was edited and peer reviewed by the Journal of Clinical Psychopharmacology. After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at https://www.cmesurvey.site/TAAR1.
Published September/October 2022

Photo -AJ Rothschild, MD in front of medical school.jpgWelcome to the September/October 2022 issue of the Journal of Clinical Psychopharmacology. There are many interesting and thought-provoking articles in this issue. I would like to highlight a few of them. On pages 427-428, Drs. Quagliato, Carta, and Nardi, in a Guest Editorial, discuss the urgent need for new medications for the treatment of panic disorder. They propose that the amygdala inhibitory network's essential involvement in the control of anxiety responses make it an ideal target. The Guest Editorial is accompanied by a podcast. Adler and colleagues in a paper entitled, “Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials" (pages 429-439) present data from the first large-scale studies to demonstrate the efficacy and safety profiles of 200 mg/day and 400 mg/day of centanafadine in adults with Attention Deficit Hyperactivity Disorder.  On pages 440-444, Zeiss and colleagues, in a paper entitled “Drug-Associated Liver Injury Related to Antipsychotics: Exploratory Analysis of Pharmacovigilance Data", discuss the association between antipsychotic medications and drug-induced liver injury. On pages 461-463, McGinnis and Yocum discuss the timely topic of infection with SARS-CoV-2 along with symptoms of COVID-19 and mental state changes which were temporally associated with lithium levels in the toxic range. Their paper, “Exposure to SARS-CoV-2, Acute Kidney Injury, and Lithium Toxicity," is accompanied by a podcast. Finally, on pages 464-469, Price and colleagues, in a paper titled “Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder," discuss the possibility that use of selective serotonin reuptake inhibitors could dampen future responses to MDMA-assisted therapy for posttraumatic stress disorder. There is also an accompanying podcast to this paper.  And as you will see, there are many other interesting Original Contributions, Brief Reports, and Letters to the Editor in the September/October 2022 issue!  ​

 Anthony J. Rothschild, MD

Editor-in-Chief

Current Issue Highlights



Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials

Adler, Lenard A.; Adams, Julie; Madera-McDonough, Jessica; More

Journal of Clinical Psychopharmacology. 42(5):429-439, September/October 2022.



Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-Analysis

Perivolaris, Argyrios; Ainsworth, Nicholas J.; Alexopoulos, George S.; More

Journal of Clinical Psychopharmacology. 42(5):489-494, September/October 2022.